|
|
 |
|
Viewing report
|
|
|
|
Competitor Analysis: Anthrax Vaccines and Therapeutics
La Merie Publishing, May 2010, Pages: 31
The present Competitive Intelligence Report about Anthrax Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies and small molecules against infection with Bacillus anthracis as of May 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Anthrax is a zoonotic disease caused by the spore-forming bacterium Bacillus anthracis. The disease most commonly occurs in mammals (e.g., cattle, sheep, goats, camels, antelope. Anthrax occurs in humans when they are exposed to infected animals or tissue from infected animals or when they are directly exposed to B. anthracis, e.g. by intentional contamination. Depending on the route of infection, anthrax disease can occur in three forms: cutaneous, gastrointestinal, and inhalation.
Currently approved anthrax vaccines in the US and in the UK are Anthrax Vaccine Absorved (AVA) and Anthrax Vaccine Precipitated (AVP), respectively, require a subcutaneous six-dose primary immunization schedule. The complex vaccination scheme, local injection site reactions, the limited spectrum of protective efficacy and the threat of the use of anthrax as a biological weapon urged governments to sponsor considerable efforts to develop novel vaccines and therapeutic antibodies against anthrax. As a result, the development pipeline substantially has grown over the last years with next generation molecules.
The report includes a compilation of currently active projects in development of vaccines, antibodies and small molecules targeting Bacillus anthracis for prophylaxis and treatment of anthrax. In addition, the report lists company-specific R&D pipelines of Anthrax Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Competitor Analysis: Cytomegalovirus (CMV) Vaccines and Therapeutics
Competitor Analysis: RSV Vaccines and Therapeutics
Competitor Analysis: Herpes Virus Vaccines and Therapeutics
Competitor Analysis: Pseudomonas Aeruginosa Vaccines and Therapeutics
Competitor Analysis: Staphylococcus aureus Vaccines and Therapeutics
Vaccine Pipeline Database: 1-Year Subscription
Human Vaccines - Global Strategic Business Report
Competitor Analysis: Anti-Infective Antibodies
Alzheimer's Disease Autoantibodies, Vaccines and Therapeutic Antibodies Pipeline, 2011
Competitor Analysis: Biologic and Immune Therapy of Staphylococcus Aureus Infections
|
|
|
|
